Application of Ramucirumab Exposure-Response Modeling to Support Dose Selection for Post Marketing Studies in Patients with Gastric Cancer

被引：0
|
作者：
O'Brien, Lisa [1 ]
Gao, Ling [2 ]
Heathman, Michael [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Bridgewater, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-36
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Visser, Sandra
    Jewell, Roxanne C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1282 - 1292
  • [22] A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
    Chuanpu Hu
    Zhenling Yao
    Yang Chen
    Bruce Randazzo
    Liping Zhang
    Zhenhua Xu
    Amarnath Sharma
    Honghui Zhou
    Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45 : 523 - 535
  • [23] Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
    Cosson, Valerie F.
    Ng, Vivian W.
    Lehle, Michaela
    Lum, Bert L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 737 - 747
  • [24] Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients
    Midde, N. M.
    Hennig, S.
    Tran, B. P.
    Qian, M.
    Tang, M.
    Singh, J.
    Vaidya, S. S.
    Lau, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S212 - S212
  • [25] Dose selection for prostate cancer patients based on dose comparison and dose response studies
    Hanks, GE
    Hanlon, AL
    Pinover, WH
    Horwitz, EM
    Price, RA
    Schultheiss, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04): : 823 - 832
  • [26] Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis
    Ismail, Mohamed
    Doelger, Eva
    Eckert, Doerthe
    Irvine, Alan D.
    Chu, Alvina D.
    Teixeira, Henrique D.
    Liu, Wei
    Nader, Ahmed
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (10) : 3139 - 3151
  • [27] Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
    Nguyen, Jenny-Hoa
    Epling, Daniel
    Dolphin, Nancy
    Paccaly, Anne
    Conrado, Daniela
    Davis, John D.
    Al-Huniti, Nidal
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (11): : 1458 - 1471
  • [28] Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
    Tabernero, Josep
    Ohtsu, Atsushi
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Ajani, Jaffer A.
    Tomasek, Jiri
    Safran, Howard
    Chandrawansa, Kumari
    Hsu, Yanzhi
    Heathman, Michael
    Khan, Azhar
    Ni, Lan
    Melemed, Allen S.
    Gao, Ling
    Ferry, David
    Fuchs, Charles S.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2215 - 2222
  • [29] Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer
    Ji, Yan
    Darstein, Christelle
    Yang, Shu
    Quinlan, Michelle
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Chakraborty, Abhijit
    Ho, Yu-Yun
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12): : 1359 - 1370
  • [30] Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
    Lu, Jian-Feng
    Rasmussen, Erik
    Karlan, Beth Y.
    Vergote, Ignace B.
    Navale, Lynn
    Kuchimanchi, Mita
    Melara, Rebeca
    Stepan, Daniel E.
    Weinreich, David M.
    Sun, Yu-Nien
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1135 - 1144
12345